Clinical Trials Logo

Mantle Cell Lymphoma clinical trials

View clinical trials related to Mantle Cell Lymphoma.

Filter by:

NCT ID: NCT02858258 Recruiting - Clinical trials for Mantle Cell Lymphoma

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Start date: July 2016
Phase: Phase 3
Study type: Interventional

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.

NCT ID: NCT02851589 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Start date: July 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

NCT ID: NCT02840539 Completed - Clinical trials for Mantle Cell Lymphoma

Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

BATMAN
Start date: October 11, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of previous treatment.

NCT ID: NCT02819583 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

NCT ID: NCT02793583 Terminated - Clinical trials for Mantle Cell Lymphoma

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

UNITY-NHL
Start date: May 25, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

NCT ID: NCT02756247 Completed - Lymphoma Clinical Trials

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Start date: May 9, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out if the combination of buparlisib and ibrutinib will lead to better treatment results in patients with relapsed or refractory Follicular lymphoma, (FL) Mantle cell lymphoma (MCL) or Diffuse Large B-cell lymphoma (DLBCL). The investigators are using buparlisib and ibrutinib because both drugs seem to block different proteins that allow cancer cells to keep growing. Blocking these proteins may help by making the cancer cells undergo cell death, which will stop uncontrolled tumor growth.

NCT ID: NCT02745769 Completed - Colorectal Cancer Clinical Trials

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Start date: October 21, 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of ramucirumab in combination with other targeted agents in participants with advanced cancers.

NCT ID: NCT02735876 Withdrawn - Clinical trials for Mantle Cell Lymphoma

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Start date: May 2016
Phase: Phase 3
Study type: Interventional

This study is evaluating the efficacy of acalabrutinib in combination with rituximab (Arm 1) versus ibrutinib (Arm 2) versus acalabrutinib (Arm 3) for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL).

NCT ID: NCT02728531 Completed - Clinical trials for Mantle Cell Lymphoma

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Start date: April 18, 2016
Phase: Phase 1
Study type: Interventional

Given the established role of high dose cytarabine (HiDAC) combined with rituximab, along with recent data showing the encouraging efficacy of bendamustine, the investigators seek to integrate the synergistic effects of these medicines in alternating cycles as induction therapy prior to autologous stem cell transplant (ASCT). Based on prior experience with bendamustine and rituximab (BR) based induction therapy, the investigators seek to evaluate the efficacy and safety of stem cell mobilization in this pilot study

NCT ID: NCT02722668 Active, not recruiting - Multiple Myeloma Clinical Trials

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Start date: May 15, 2017
Phase: Phase 2
Study type: Interventional

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.